This study evaluated the 5-year biochemical progression-free survival (bPFS) rate and late toxicities associated with conventional radiotherapy (CRT) and stereotactic body radiotherapy (SBRT) in Chinese patients with low-to intermediate-risk prostate cancer. A retrospective analysis was conducted in patients with low- to intermediate-risk prostate cancer who received CRT (76 Gy in 38 fractions) or SBRT (36.25 Gy in 5 fractions) between 2015 and 2019 at a hospital in Hong Kong.